A more recent update from Rodman & Renshaw - dated 6th Sept 2016
http://cynata.com/wp-content/uploads/2016/09/Fujifilm-update-6Sept16.pdf
Non-binding term sheet executed. Yesterday, Cynata announced that it had signed a non-binding development and commercialization term sheet with Fujifilm Corp. of Japan covering certain Cynata technology, including the Australian firm’s lead induced pluripotent stem cell (iPSC) derived therapeutic mesenchymal stem cell (MSC)- based product candidate, CYP-001. Pursuant to this term sheet, the parties are to finalize a definitive agreement, which Cynata management expects to be completed before the end of 2016. In the wake of the signing of this agreement, we reiterate our Buy rating and 12-month price target of A$1.00 per share on Cynata.
Rodman & Renshaw
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
27.0¢ |
Change
0.030(12.5%) |
Mkt cap ! $48.50M | |||
| Open | High | Low | Value | Volume |
| 26.0¢ | 29.5¢ | 26.0¢ | $113.1K | 420.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4999 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 27.5¢ | 3935 | 1 |
View Market Depth
| Last trade - 16.10pm 21/06/2024 (20 minute delay) ? |
| CYP (ASX) Chart |